Tourmaline Bio, Inc. TRML · Stock Open Tourmaline Bio, Inc. in new tab
Tourmaline Bio, Inc. Analysis (TRML)
Is Tourmaline Bio, Inc. a good investment? Tourmaline Bio, Inc. (TRML) is currently trading at 47.98 USD.
Earnings Schedule: Tourmaline Bio, Inc. is expected to release its next earnings report on April 30, 2026. The market consensus estimate for Forward EPS is -3.64.
Investor FAQ
Does Tourmaline Bio, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Tourmaline Bio, Inc.?
Tourmaline Bio, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be April 30, 2026. The company currently has a trailing EPS of -3.44.
Company Profile
Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The company's development pipeline comprises medicines and therapies for the atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED). The company was formerly known as Tourmaline Bio, LLC and changed its name to Tourmaline Bio, Inc. in September 2022. Tourmaline Bio, Inc. was founded in 2021 and is headquartered in New York, New York. Tourmaline Bio, Inc. operates as a subsidiary of Novartis AG.
| Year | Total Dividends |
|---|---|
| ▸2023 |
1.51 USD
|
| Oct. 20, 2023 | 1.5118 |
| Split Date | Split Ratio to 1 |
|---|---|
| Oct. 20, 2023 | 0.100000 |
Community Discussion